Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortization of Deferred Charges (2021)

ARS Pharmaceuticals (SPRY) has disclosed Amortization of Deferred Charges for 1 consecutive years, with $1000.0 as the latest value for Q2 2021.

  • Quarterly Amortization of Deferred Charges changed N/A to $1000.0 in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Dec 2021, changed N/A year-over-year, with the annual reading at $2000.0 for FY2021, 93.55% down from the prior year.
  • Amortization of Deferred Charges hit $1000.0 in Q2 2021 for ARS Pharmaceuticals, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1000.0 in Q1 2021 to a low of $1000.0 in Q1 2021.